Boston Trust Walden Corp Sells 73 Shares of Atrion Co. (NASDAQ:ATRI)

Boston Trust Walden Corp decreased its position in shares of Atrion Co. (NASDAQ:ATRI) by 0.2% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 35,729 shares of the medical instruments supplier’s stock after selling 73 shares during the period. Boston Trust Walden Corp owned approximately 2.03% of Atrion worth $16,165,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Penn Mutual Asset Management LLC bought a new stake in shares of Atrion during the 4th quarter worth approximately $1,949,000. Public Employees Retirement System of Ohio bought a new stake in Atrion during the 1st quarter valued at about $2,299,000. Citizens Financial Group Inc. RI purchased a new stake in Atrion in the 4th quarter valued at about $1,114,000. State Board of Administration of Florida Retirement System bought a new stake in shares of Atrion during the first quarter valued at approximately $421,000. Finally, Sei Investments Co. increased its holdings in Atrion by 59.7% during the 1st quarter. Sei Investments Co. now owns 1,774 shares of the medical instruments supplier’s stock worth $822,000 after purchasing an additional 663 shares during the period. Institutional investors own 66.19% of the company’s stock.

Atrion Stock Performance

NASDAQ:ATRI traded up $0.40 during trading hours on Friday, reaching $459.85. The company’s stock had a trading volume of 27,640 shares, compared to its average volume of 23,264. Atrion Co. has a 12 month low of $274.98 and a 12 month high of $503.24. The stock has a 50 day moving average price of $455.77 and a two-hundred day moving average price of $426.90. The company has a market capitalization of $809.34 million, a P/E ratio of 43.22 and a beta of 0.69.

Atrion (NASDAQ:ATRI) last posted its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $0.23 earnings per share for the quarter. The firm had revenue of $48.77 million during the quarter. Atrion had a return on equity of 7.75% and a net margin of 10.60%.

Atrion Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 28th. Shareholders of record on Friday, June 14th were paid a dividend of $2.20 per share. The ex-dividend date of this dividend was Friday, June 14th. This represents a $8.80 dividend on an annualized basis and a dividend yield of 1.91%. Atrion’s payout ratio is currently 82.71%.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on Atrion in a report on Sunday. They issued a “sell” rating for the company.

Atrion Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.